Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel O'Reilly

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Journal of Inherited Metabolic Disease|December 10, 2020
Maple syrup urine disease: Clinical outcomes, metabolic control, and genotypes in a screened population after four decades of newborn bloodspot screening in the Republic of IrelandDaniel O'Reilly, Ellen Crushell, Joanne Hughes, et al.
Blood Vessels, Thrombosis & Hemostasis|May 7, 2026
Cross-species comparison of platelet proteomes reveals developmentally regulated metabolic and inflammatory changesChristopher S Thom, Xinyue Ma, Henry A Feldman, et al.
Advanced Materials (Deerfield Beach, Fla.)|February 4, 2016
Biomaterial-Enhanced Cell and Drug Delivery: Lessons Learned in the Cardiac Field and Future PerspectivesHugh S O'Neill, Laura B Gallagher, Janice O'Sullivan, et al.
Nucleic Acids Research|January 12, 2026
Presence of phosphodiester backbone, but not nucleobases, in the guide's 3' terminal region is necessary for RISC loading and target cleavage in vitro and in vivoDaniel O'Reilly, Raymond C Furgal, Vella M Ross, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 26, 2023
Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington's diseaseDaniel O'Reilly, Jillian Belgrad, Chantal Ferguson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 13, 2023
Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington's diseaseDaniel O'Reilly, Jillian Belgrad, Chantal Ferguson, et al.
Biorxiv : the Preprint Server for Biology|February 9, 2026
Chemical control of 2'-hydroxyl-dependent Cas9 target engagement enables CRISPR RNA ribose replacementAdrian A Pater, Halle M Barber, Sruthi Sudhakar, et al.
Science Translational Medicine|March 18, 2026
Lowering the <i>HTT1a</i> transcript as an effective therapy for Huntington's disease in a knockin mouse modelAikaterini Smaragdi Papadopoulou, Julia Alterman, Christian Landles, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Blocking somatic repeat expansion and lowering huntingtin via RNA interference synergize to prevent Huntington's disease pathogenesis in miceJillian Belgrad, Ashley Summers, Christian Landles, et al.
Nucleic Acids Research|June 23, 2025
Systematic analysis of siRNA and mRNA features impacting fully chemically modified siRNA efficacySarah M Davis, Samuel Hildebrand, Hannah J MacMillan, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Journal of Inherited Metabolic Disease|December 10, 2020
Maple syrup urine disease: Clinical outcomes, metabolic control, and genotypes in a screened population after four decades of newborn bloodspot screening in the Republic of IrelandDaniel O'Reilly, Ellen Crushell, Joanne Hughes, et al.
Blood Vessels, Thrombosis & Hemostasis|May 7, 2026
Cross-species comparison of platelet proteomes reveals developmentally regulated metabolic and inflammatory changesChristopher S Thom, Xinyue Ma, Henry A Feldman, et al.
Advanced Materials (Deerfield Beach, Fla.)|February 4, 2016
Biomaterial-Enhanced Cell and Drug Delivery: Lessons Learned in the Cardiac Field and Future PerspectivesHugh S O'Neill, Laura B Gallagher, Janice O'Sullivan, et al.
Nucleic Acids Research|January 12, 2026
Presence of phosphodiester backbone, but not nucleobases, in the guide's 3' terminal region is necessary for RISC loading and target cleavage in vitro and in vivoDaniel O'Reilly, Raymond C Furgal, Vella M Ross, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 26, 2023
Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington's diseaseDaniel O'Reilly, Jillian Belgrad, Chantal Ferguson, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 13, 2023
Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington's diseaseDaniel O'Reilly, Jillian Belgrad, Chantal Ferguson, et al.
Biorxiv : the Preprint Server for Biology|February 9, 2026
Chemical control of 2'-hydroxyl-dependent Cas9 target engagement enables CRISPR RNA ribose replacementAdrian A Pater, Halle M Barber, Sruthi Sudhakar, et al.
Science Translational Medicine|March 18, 2026
Lowering the <i>HTT1a</i> transcript as an effective therapy for Huntington's disease in a knockin mouse modelAikaterini Smaragdi Papadopoulou, Julia Alterman, Christian Landles, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Blocking somatic repeat expansion and lowering huntingtin via RNA interference synergize to prevent Huntington's disease pathogenesis in miceJillian Belgrad, Ashley Summers, Christian Landles, et al.
Nucleic Acids Research|June 23, 2025
Systematic analysis of siRNA and mRNA features impacting fully chemically modified siRNA efficacySarah M Davis, Samuel Hildebrand, Hannah J MacMillan, et al.
Pageof 8